

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access
SLEEPING SICKNESS			SCYX-1330682 SCYX-1608210 +				Acoziborole + Fexinidazole for <i>T.b. rhodesiense</i> +		Fexinidazole for <i>T.b.gambiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)*
LEISHMANIASIS	Screening	Leishmaniasis Hit-to-lead	DNDI-5421 DNDI-5610 +	DNDI-6174 +	DNDI-6148 +		New CL combination	New VL treatments (Latin America)	SSG&PM (East Africa)*
		NTD Drug Discovery Booster Hit-to-lead	Amino pyrazoles +	GSK3494245 DDD1305143 +	DNDI-0690 +		New treatments for PKDL	New treatments for HIV/VL	New VL treatments (South Asia)*
		Daiichi Sankyo Hit-to-lead	CF series +	CpG-D35 for CL +	GSK3186899 DDD853651 +		Miltefosine + paromomycin combination (Africa)		
			Leishmaniasis L205 series +		Novartis LXE408 +				
CHAGAS DISEASE	Screening	Hit-to-lead	C205 series +	Biomarkers		Fexinidazole +	New benznidazole regimens +		Benznidazole paediatric dosage forms*
		NTD Drug Discovery Booster Hit-to-lead							
		Daiichi Sankyo Hit-to-lead							
FILARIA: RIVER BLINDNESS				Macrofilaricide CCG166 +	Oxfendazole +	Emodepside + TylAMac (ABBV-4083) +			
MYCETOMA						Fosravuconazole +			
HIV					5 FC (cryptococcal meningitis)			4-in-1 (ABC/3TC/LPV/r)	Super-booster therapy for children with HIV/TB* 2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC
HEPATITIS C							Ravidasvir + sofosbuvir +	Ravidasvir +	
MALARIA ★									Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*

★ Implementation transferred to the Medicines for Malaria Venture in 2015

+ NCE (New chemical entity)

\* Treatments delivered by DNDi